Among patients with CIMP+ tumors, adjuvant chemotherapy was not an independent predictor of outcome (HR=0

Among patients with CIMP+ tumors, adjuvant chemotherapy was not an independent predictor of outcome (HR=0.8; 95% CI, 0.32.0). impartial conversation between 5-FU treatment and CIMP status (hazard ratio [HR]=0.6; 95% confidence interval [CI], .5.8). Among patients with CIMP+ tumors, adjuvant chemotherapy was not an independent predictor of end result (HR=0.8; 95% CI, 0.32.0). In patients who did not Clemastine fumarate receive adjuvant 5-FU chemotherapy, CIMP status was the only impartial predictor of survival (HR=2.0; 95% CI, 1.13.8) == Conclusion == Patients with CIMP+ colorectal tumors do not benefit from 5-FUbased adjuvant chemotherapy. Keywords:Colon cancer, 5-FU adjuvant chemotherapy, DNA methylation, response to malignancy therapy == INTRODUCTION == Colorectal malignancy (CRC) is usually a common disease that accounts for a large proportion of cancer cases in Western countries. Approximately a 1015% of CRC are caused by epigenetic silencing of the gene MLH1, provoking a characteristic molecular phenotype called microsatellite instability (MSI), displaying a form of genetic instability characterized by the accumulation of numerous mutations within repetitive sequences of DNA in non-encoding microsatellite regions1,2. In the last few years, there has been a growing acknowledgement of the presence of a new pathway for CRC pathogenesis, which involves the transcriptional silencing of tumor suppressor genes by hypermethylation of CpG islands surrounding the promoter regions of numerous genes3. Tumors with such features are classified as having the CpG RICTOR island methylator phenotype (CIMP)4, and it is now believed that as many as one-third to one-half of all CRCs may evolve through this pathway57. CIMP tumors with methylation-induced silencing ofMLH1constitute the majority of sporadic MSI CRCs8. However, most CIMP-positive tumors are associated with microsatellite stability (MSS)9. These CIMP MSS tumors share certain clinical and pathological features with MSI CRCs, including a predilection for females, advanced age of disease onset, predilection for proximal colon, poor differentiation and mucinous histology10. Patients with MSI CRCs have a better prognosis11and do not obtain benefit from 5-fluorouracil (5-FU)-based adjuvant chemotherapy1216. Since a significant majority of CIMP tumors share features of sporadic MSI cancers, one would suspect that they would have a similar therapeutic response. However, insufficient attention has been paid to this important clinical issue, and there is only limited published data on prognosis in CRCs with CIMP1719, and the response to chemotherapy in this type of CRC is usually unclear or worse, contradictory2022. The present study was designed to better understand the prognosis of patients with CIMP-positive CRCs, and to determine the response to adjuvant 5-FU chemotherapy using a large population-based collection of CRCs. This information could be crucial in the choice of chemotherapeutic treatment, especially considering recently developed new inhibitors of DNA methylation23. Our results suggest that CIMP-positive CRCs, similarly to MSI tumors, do not obtain a significant benefit from 5-FU-based adjuvant chemotherapy. == MATERIALS AND METHODS == == Clinical specimens == This study included 302 CRC patients that were enrolled as part of the EPICOLON project, a population-based study on CRC24,25. These patients were randomly selected from a previously Clemastine fumarate explained cohort of patients for which follow-up data were available14,15. The study was approved by the institutional ethics committee of each participant hospital and written knowledgeable consent was obtained Clemastine fumarate from all patients. The integrity of the mismatch repair system was evaluated by MSI screening and immunostaining for MLH1, MSH2, MSH6 and PMS2 proteins. Tumor mismatch repair (MMR) deficiency was defined by either obtaining MSI-high (observe below) or the loss of MLH1, MSH2, MSH6 or PMS2 protein expression by immunohistochemistry. Adjuvant chemotherapy was administered according to standard clinical criteria. Adjuvant chemotherapy with 5-fluorouracil (5-FU) was given to patients with stage II and III tumors following standard schedules and doses. Oncologists that decided to administer adjuvant treatment were blinded to the MMR or CIMP tumor status. == Tumor MSI analysis == MSI screening was performed using either the 5-marker panel proposed by the National Malignancy Institute or a pentaplex of mononucleotide repeats, and tumors were classified.